Effectiveness O O O O
of O O O O
mRNA O O O O
Covid-19 O O O O
Vaccine O O O O
among O O O O
U.S. O O O O
Health O O O O
Care O O O O
Personnel O O O O
- O O O O
PMID: O O O O
34551224 O O O O
- O O O O
PMCID: O O O O
[PMC8482809](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8482809/) O O O O
- O O O O
DOI: O O O O
[10.1056/NEJMoa2106599](https://doi.org/10.1056/nejmoa2106599) O O O O
Effectiveness O O O O
of O O O O
mRNA O O O O
Covid-19 O O O O
Vaccine O O O O
among O O O O
U.S. O O O O
Health O O O O
Care O O O O
Personnel O O O O
Abstract O O O O
Background: O O O O
The Reason 5 O O
prioritization Reason 5 O O
of Reason 5 O O
U.S. Reason 5 O O
health Reason 5 O O
care Reason 5 O O
personnel Reason 5 O O
for Reason 5 O O
early Reason 5 O O
receipt Reason 5 O O
of Reason 5 O O
messenger Reason 5 O O
RNA Reason 5 O O
(mRNA) Reason 5 O O
vaccines Reason 5 O O
against Reason 5 O O
severe Reason 5 O O
acute Reason 5 O O
respiratory Reason 5 O O
syndrome Reason 5 O O
coronavirus Reason 5 O O
2 Reason 5 O O
(SARS-CoV-2), Reason 5 O O
the Reason 5 O O
virus Reason 5 O O
that Reason 5 O O
causes Reason 5 O O
coronavirus Reason 5 O O
disease Reason 5 O O
2019 Reason 5 O O
(Covid-19), Reason 5 O O
allowed Reason 5 O O
for Reason 5 O O
the Reason 5 O O
evaluation Reason 5 O O
of Reason 5 O O
the Reason 5 O O
effectiveness Reason 5 O O
of Reason 5 O O
these Reason 5 O O
new Reason 5 O O
vaccines Reason 5 O O
in Reason 5 O O
a Reason 5 O O
real-world Reason 5 O O
setting. Reason 5 O O
Methods: O O O O
We O O O O
conducted O O O O
a O O O O
test-negative O O O O
case-control O O O O
study O O O O
involving O O O O
health O O O O
care O O O O
personnel O O O O
across O O O O
25 O O O O
U.S. O O O O
states. O O O O
Cases O O O O
were O O O O
defined O O O O
on O O O O
the O O O O
basis O O O O
of O O O O
a O O O O
positive O O O O
polymerase-chain-reaction O O O O
(PCR) O O O O
or O O O O
antigen-based O O O O
test O O O O
for O O O O
SARS-CoV-2 O O O O
and O O O O
at O O O O
least O O O O
one O O O O
Covid-19-like O O O O
symptom. O O O O
Controls O O O O
were O O O O
defined O O O O
on O O O O
the O O O O
basis O O O O
of O O O O
a O O O O
negative O O O O
PCR O O O O
test O O O O
for O O O O
SARS-CoV-2, O O O O
regardless O O O O
of O O O O
symptoms, O O O O
and O O O O
were O O O O
matched O O O O
to O O O O
cases O O O O
according O O O O
to O O O O
the O O O O
week O O O O
of O O O O
the O O O O
test O O O O
date O O O O
and O O O O
site. O O O O
Using O O O O
conditional O O O O
logistic O O O O
regression O O O O
with O O O O
adjustment O O O O
for O O O O
age, O O O O
race O O O O
and O O O O
ethnic O O O O
group, O O O O
underlying O O O O
conditions, O O O O
and O O O O
exposures O O O O
to O O O O
persons O O O O
with O O O O
Covid-19, O O O O
we O O O O
estimated O O O O
vaccine O O O O
effectiveness O O O O
for O O O O
partial O O O O
vaccination O O O O
(assessed O O O O
14 O O O O
days O O O O
after O O O O
receipt O O O O
of O O O O
the O O O O
first O O O O
dose O O O O
through O O O O
6 O O O O
days O O O O
after O O O O
receipt O O O O
of O O O O
the O O O O
second O O O O
dose) O O O O
and O O O O
complete O O O O
vaccination O O O O
(assessed O O O O
7 O O O O
days O O O O
after O O O O
receipt O O O O
of O O O O
the O O O O
second O O O O
dose). O O O O
Results: O O O O
The O O O O
study O O O O
included O O O O
1482 O O O O
case O O O O
participants O O O O
and O O O O
3449 O O O O
control O O O O
participants. O O O O
Vaccine Reason 5 O O
effectiveness Reason 5 O O
for Reason 5 O O
partial Reason 5 O O
vaccination Reason 5 O O
was Reason 5 O O
77.6% Reason 5 O O
(95% Reason 5 O O
confidence Reason 5 O O
interval Reason 5 O O
[CI], Reason 5 O O
70.9 Reason 5 O O
to Reason 5 O O
82.7) Reason 5 O O
(Pfizer-BioNTech) Reason 5 O O
to Reason 5 O O
94.2) Reason 5 O O
with Reason 5 O O
the Reason 5 O O
mRNA-1273 Reason 5 O O
vaccine Reason 5 O O
(Moderna); Reason 5 O O
for Reason 5 O O
complete Reason 5 O O
vaccination, Reason 5 O O
vaccine Reason 5 O O
effectiveness Reason 5 O O
was Reason 5 O O
88.8% Reason 5 O O
CI, Reason 5 O O
to Reason 5 O O
91.8) Reason 5 O O
and Reason 5 O O
96.3% Reason 5 O O
(95% Reason 5 O O
CI, Reason 5 O O
91.3 Reason 5 O O
to Reason 5 O O
98.4), Reason 5 O O
respectively. Reason 5 O O
Vaccine Reason 5 O O
effectiveness Reason 5 O O
was Reason 5 O O
similar Reason 5 O O
in Reason 5 O O
subgroups Reason 5 O O
defined Reason 5 O O
according Reason 5 O O
to Reason 5 O O
age Reason 5 O O
(<50 Reason 5 O O
years Reason 5 O O
or Reason 5 O O
50 Reason 5 O O
years), Reason 5 O O
race Reason 5 O O
and Reason 5 O O
ethnic Reason 5 O O
group, Reason 5 O O
presence Reason 5 O O
of Reason 5 O O
underlying Reason 5 O O
conditions, Reason 5 O O
and Reason 5 O O
level Reason 5 O O
of Reason 5 O O
patient Reason 5 O O
contact. Reason 5 O O
Estimates Reason 5 O O
of Reason 5 O O
vaccine Reason 5 O O
effectiveness Reason 5 O O
were Reason 5 O O
lower Reason 5 O O
during Reason 5 O O
weeks Reason 5 O O
9 Reason 5 O O
through Reason 5 O O
14 Reason 5 O O
than Reason 5 O O
during Reason 5 O O
weeks Reason 5 O O
3 Reason 5 O O
through Reason 5 O O
8 Reason 5 O O
after Reason 5 O O
receipt Reason 5 O O
of Reason 5 O O
the Reason 5 O O
second Reason 5 O O
dose, Reason 5 O O
but Reason 5 O O
confidence Reason 5 O O
intervals Reason 5 O O
overlapped Reason 5 O O
widely. Reason 5 O O
Conclusions: O O O O
The Reason 5 O O
BNT162b2 Reason 5 O O
and Reason 5 O O
mRNA-1273 Reason 5 O O
vaccines Reason 5 O O
were Reason 5 O O
highly Reason 5 O O
effective Reason 5 O O
under Reason 5 O O
real-world Reason 5 O O
conditions Reason 5 O O
in Reason 5 O O
preventing Reason 5 O O
symptomatic Reason 5 O O
Covid-19 Reason 5 O O
in Reason 5 O O
health Reason 5 O O
care Reason 5 O O
personnel, Reason 5 O O
including Reason 5 O O
those Reason 5 O O
at Reason 5 O O
risk Reason 5 O O
for Reason 5 O O
severe Reason 5 O O
Covid-19 Reason 5 O O
and Reason 5 O O
those Reason 5 O O
in Reason 5 O O
racial Reason 5 O O
and Reason 5 O O
ethnic Reason 5 O O
groups Reason 5 O O
that Reason 5 O O
have Reason 5 O O
been Reason 5 O O
disproportionately Reason 5 O O
affected Reason 5 O O
by Reason 5 O O
the Reason 5 O O
pandemic. Reason 5 O O
(Funded Reason 5 O O
by Reason 5 O O
the Reason 5 O O
Centers Reason 5 O O
for Reason 5 O O
Disease Reason 5 O O
Control Reason 5 O O
and Reason 5 O O
Prevention.). Reason 5 O O
Copyright O O O O
Â© O O O O
2021 O O O O
Massachusetts O O O O
Medical O O O O
Society. O O O O
Figures O O O O
Similar O O O O
articles O O O O
- O O O O
[Association O O O O
Between O O O O
3 O O O O
Doses O O O O
of O O O O
mRNA O O O O
COVID-19 O O O O
Vaccine O O O O
and O O O O
Symptomatic O O O O
Infection O O O O
Caused O O O O
by O O O O
the O O O O
SARS-CoV-2 O O O O
and O O O O
Antibody O O O O
Responses O O O O
to O O O O
Moderna O O O O
and O O O O
Pfizer-BioNTech O O O O
COVID-19 O O O O
Vaccines O O O O
among O O O O
Hospitalized O O O O
Veterans O O O O
- O O O O
Five O O O O
Veterans O O O O
Affairs O O O O
Medical O O O O
Centers, O O O O
United O O O O
States, O O O O
February O O O O
1-September O O O O
30, O O O O
2021.](/34882654/)MMWR O O O O
[Interim O O O O
Estimates O O O O
of O O O O
Vaccine O O O O
Effectiveness O O O O
of O O O O
BNT162b2 O O O O
and O O O O
mRNA-1273 O O O O
COVID-19 O O O O
Vaccines O O O O
in O O O O
Preventing O O O O
SARS-CoV-2 O O O O
Infection O O O O
Among O O O O
Health O O O O
Care O O O O
Personnel, O O O O
First O O O O
Responders, O O O O
and O O O O
Other O O O O
Essential O O O O
and O O O O
Frontline O O O O
Workers O O O O
- O O O O
Eight O O O O
U.S. O O O O
Locations, O O O O
December O O O O
2020-March O O O O
2021.](/33793460/)MMWR O O O O
[Effectiveness O O O O
of O O O O
a O O O O
Third O O O O
Dose O O O O
of O O O O
Pfizer-BioNTech O O O O
and O O O O
Moderna O O O O
Vaccines O O O O
in O O O O
Preventing O O O O
COVID-19 O O O O
Hospitalization O O O O
Among O O O O
Immunocompetent O O O O
and O O O O
Immunocompromised O O O O
Adults O O O O
- O O O O
United O O O O
States O O O O
